Effect Of Angiotensin-receptor Neprilysin Inhibitor By Different Dose On Left Ventricular Reverse Remodeling According To On-treatment Blood Pressure

Chan Joo Lee,Jaewon Oh,Se-Eun Kim,Seok-Min Kang

DOI: https://doi.org/10.1016/j.cardfail.2023.10.297

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Background Contemporary heart failure guidelines suggest that angiotensin receptor-neprilysin inhibitor (ARNI) should be titrated to a target dose of 400 mg daily in patients with heart failure with reduced ejection fraction (HFrEF, EF < 40%). This study aimed to investigate whether ARNI's effect on left ventricular reverse remodeling (LVRR) was affected by different doses and on-treatment blood pressure (BP). Methods This study retrospectively analyzed 1,165 patients treated with ARNI after diagnosis of HFrEF at a single tertiary hospital from 2017 to 2022. Every patient had follow-up echocardiographic data, and on-treatment office BPs were measured on the same day. LVRR was defined as ≥10% absolute improvement in LV ejection fraction (LVEF) and follow-up LVEF ≥40%. We divided the subject into two groups [the higher BP group (on-treatment systolic BP ≥100mHg; N=908) versus the lower BP group (on-treatment systolic BP <100mHg; N=257)]. We analyzed the association between the achieved dose of ARNI and LVRR using multiple logistic regression in both the higher and lower BP groups. Results More LVRR was noted in the higher BP group than in the lower BP group (38.5% vs. 26.5%, p<0.001). The number of patients with achieved dose of ARNI (low-dose: <100mg/day; intermediate-dose: ≥100mg and <200mg/day; high-dose: ≥200mg/day) was different between 2 groups (the higher BP group: 31.7%, 34.1%, 34.1% vs. the lower BP group: 57.6%, 28.8%, 13.6%, respectively; p<0.001). High-dose ARNI was associated with more LVRR in the total patients (low dose: reference; intermediate dose: OR=1.19 [95% CI, 0.85-1.66], p=0.322; high dose: OR=1.82 [95% CI, 1.29-2.56], p=0.001) and in the higher BP group (low dose: reference; intermediate dose: OR=1.06 [95% CI, 0.72-1.56], p=0.785; high dose: OR =1.57 [95% CI, 1.07-2.31], p=0.022). Although there was no significant relationship between high dose ARNI and LVRR in the lower BP group (low dose: reference; intermediate dose: OR=1.10 [95% CI, 0.53-2.27], p=0.796; high dose: OR=1.08 [95% CI, 0.42-2.78], p=0.874), the association between LVRR and dose of ARNI was not changed by on-treatment systolic BP (p for interaction between 2 groups: 0.879). Conclusion In HFrEF patients, high-dose ARNI was related to LVRR, and this relationship was dominant in the patients with higher on-treatment BP. In contrast, there was no significant association between the achieved dose of ARNI and LVRR in the patients with lower on-treatment BP.

cardiac & cardiovascular systems